Arkadios Wealth Advisors Acquires 410 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Arkadios Wealth Advisors boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 61.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,081 shares of the pharmaceutical company’s stock after purchasing an additional 410 shares during the quarter. Arkadios Wealth Advisors’ holdings in Vertex Pharmaceuticals were worth $435,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. InTrack Investment Management Inc lifted its position in shares of Vertex Pharmaceuticals by 49.9% during the 4th quarter. InTrack Investment Management Inc now owns 2,132 shares of the pharmaceutical company’s stock valued at $878,000 after acquiring an additional 710 shares during the period. TrueWealth Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 35.4% during the fourth quarter. TrueWealth Advisors LLC now owns 1,037 shares of the pharmaceutical company’s stock valued at $418,000 after purchasing an additional 271 shares during the period. Arthur M. Cohen & Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 3.5% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 890 shares of the pharmaceutical company’s stock worth $358,000 after purchasing an additional 30 shares in the last quarter. Brooklyn Investment Group grew its stake in shares of Vertex Pharmaceuticals by 1.8% in the 4th quarter. Brooklyn Investment Group now owns 1,906 shares of the pharmaceutical company’s stock valued at $768,000 after buying an additional 33 shares during the period. Finally, Merit Financial Group LLC increased its position in Vertex Pharmaceuticals by 77.6% in the 4th quarter. Merit Financial Group LLC now owns 4,931 shares of the pharmaceutical company’s stock valued at $1,986,000 after buying an additional 2,155 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

VRTX opened at $428.00 on Thursday. The company has a market capitalization of $110.22 billion, a price-to-earnings ratio of -215.08, a PEG ratio of 2.17 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $438.10 and a 200-day moving average price of $465.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the previous year, the firm posted $3.67 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on VRTX shares. Royal Bank of Canada raised their price objective on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Stifel Nicolaus boosted their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research note on Monday, December 16th. Barclays dropped their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research note on Friday, December 20th. Scotiabank boosted their target price on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research report on Monday, December 23rd. Finally, Citigroup initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.